ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 336

Cluster Analysis Of Psoriatic Arthritis Patients At Follow-Up

Arane Thavaneswaran1, Vinod Chandran2 and Dafna D. Gladman2, 1Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Psoriatic arthritis

  • Tweet
  • Email
  • Print
Session Information

Title: Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: Psoriatic Arthritis: Clinical Aspects and Treatment I

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Our previous research showed that baseline characteristics would enable the sub-categorization of psoriatic arthritis (PsA) into the distinct phenotypic groups of axial and peripheral disease using cluster analysis (CA). We aimed to determine if demographic and disease characteristics of PsA patients with at least five years of follow-up can be clustered into distinct groups.

Methods:

527 PsA patients from an observational cohort of patients seen from 1978 to 2013. Patients had at least 5 years of follow-up and genetic information in order to be included in the analysis. CA using Ward’s method was conducted to identify groups of patients based on the following characteristics at follow-up:  gender, type of psoriasis (type I or II), duration of PsA, race, family history of psoriasis, ESR, severe PASI, psoriasis vulgaris, nail disease, dactylitis, swollen joint count, damaged joint count, axial disease, presence of arthritis mutilans, presence of arthritis prior to psoriasis, HLA-B*27 and HLA-C*06. 7 clusters were formed and matched to non-overlapping arthritis patterns:  distal arthritis, oligoarthritis, polyarthritis, axial only, distal arthritis and axial, oligoarthritis & axial, and polyarthritis & axial. Comparisons between the clusters and arthritis patterns were conducted using t-tests and Chi-squared analysis.

Results:

The baseline characteristics of the 527 patients were as follows: 306 (58.1%) males, mean age at diagnosis of PsA 28.3 (14.2) yrs, mean age at first visit 42.5 (12.3) yrs, mean duration of PsA 6.8 (8.0) years, mean active joint count 10.6 (9.2), mean PASI 5.2 (8.1), mean Steinbrocker score 12.7 (25.9), HLA-B*27 94 (18%)]. At follow-up, mean age was 57.6 (12.6) yrs, mean PASI 4.6 (6.6), mean Steinbrocker score 28.0 (37.3) with an average follow-up of 15.0 (7.6) yrs. Two main clusters of patients were identified. One consisted of distal arthritis, oligoarthritis and polyarthritis and the other of axial only, distal and axial, oligoarthritis & axial, and polyarthritis & axial, thus clearly identifying patients into peripheral and axial disease. Comparison of the two clusters showed more patients with psoriasis vulgaris among patients with peripheral disease. Patients falling into the axial disease cluster had a higher prevalence of males and HLA-B*27, higher PASI, more dactylitis, higher clinically damaged joint and swollen joint count, more axial disease, more arthritis mutilans and more patients who developed arthritis first.

Conclusion: Based on patients’ characteristics at follow-up, CA analysis separated PsA patients into two predominant arthritis patterns coinciding with the results that looked at a the same cohort  at baseline with the exclusion of B27 and C6 as clustering variables. The study provides further evidence to classify patients into just two groups based on the presence or absence of axial arthritis not only at baseline but also at follow-up.

Table: Comparison of two clusters

Variable

Frequency (%) or Mean (sd)

p-value

Cluster I

Cluster II

Age at diagnosis of Ps (>40 vs. <=40)

63 (20.9%)

44 (19.5%)

0.68

Duration of PsA

21.3 (11.1)

22.5 (9.8)

0.16

Gender (Males)

149 (49.5%)

157 (69.5%)

<0.0001

Race (Caucasian vs. others)

267 (88.7%)

210 (92.9%)

0.10

Family history of Psoriasis

142 (47.7%)

116 (51.6%)

0.38

Nail disease

124 (44.6%)

106 (51.0%)

0.16

Dactylitis

6 (2.0%)

18 (8.3%)

0.001

Psoriasis vulgaris

236 (81.9%)

142 (66.4%)

<0.0001

Severe PASI (>=10)

18 (7.2%)

30 (19.4%)

0.0002

ESR

15.9 (15.8)

15.3 (17.2)

0.69

Swollen joint count

0.74 (1.72)

1.40 (3.4)

0.008

Clinically damaged joints

8.4 (12.2)

14.7 (16.4)

<0.0001

Axial disease

104 (34.9%)

177 (79.0%)

<0.0001

Presence of arthritis mutilans

76 (25.3%)

99 (43.8%)

<0.0001

Presence of arthritis prior to psoriasis

30 (10.0%)

15 (6.6%)

0.18

HLA-B*27

44 (14.6%)

50 (22.1%)

0.03

HLA-C*6

83 (27.6%)

64 (28.3%)

0.85


Disclosure:

A. Thavaneswaran,
None;

V. Chandran,
None;

D. D. Gladman,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cluster-analysis-of-psoriatic-arthritis-patients-at-follow-up/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology